Association of Symptoms and Cytokines in Prostate Cancer Patients Receiving Radiation Treatment

Dirksen, Shannon Ruff; Kirschner, Kenneth F.; Belyea, Michael

doi:10.1177/1099800413490228

Cited by 21 publications

(21 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a subsample of participants from this study, our prior reported findings suggested the lack of a strong association at both pre-and posttreatment between cytokine levels and symptoms. 49 …”

Section: Discussionmentioning

confidence: 99%

Transitions in Symptom Cluster Subgroups Among Men Undergoing Prostate Cancer Radiation Therapy

et al. 2016

Self Cite

View full text Add to dashboard Cite

Background Prostate cancer is a common type of cancer worldwide and in the United States. However, little information has been reported on the symptoms of men overtime who receive radiation therapy. Objective Identify subgroups of men at pre-and post radiation therapy on general and treatment-related symptoms and to determine transitions in subgroup membership overtime. Methods Men (n=84) receiving completed questionnaires on fatigue, insomnia, pain, depression, anxiety, and sexual, urinary and bowel problems at pre-and posttreatment. Latent class analysis identified subgroups. One-way ANOVAs determined subgroups differed on symptoms, participant characteristics, and quality of life. Latent transition analysis examined subgroup transitions overtime. Results At pretreatment four subgroups identified: Resilient group with little to no symptom reporting, Adjusted group with moderately high treatment-related symptoms, low insomnia, depression, and anxiety, Distressed group consistently high on most symptoms, and Emerging group with moderately high fatigue, depression, and anxiety with few treatment-related symptoms. At posttreatment similar results to groups at pretreatment: Resilient, Adjusted and Distressed groups with an Impacted group having high pain, insomnia, depression, urinary, and bowel symptoms. Quality of life and participant characteristics further distinguished groups at pre-and posttreatment. Income level predicted a transition in group membership. Conclusions Men can be classified into distinctly different subgroups overtime. Implications for Practice Assessment and intervention with men in subgroups such as Distressed and Emerging before and during treatment may lessen potential for remaining distressed, or moving into Impacted group where symptom severity is high at posttreatment. Interventions to reduce multiple symptoms are vitally needed.

show abstract

Section: Discussionmentioning

confidence: 99%

Transitions in Symptom Cluster Subgroups Among Men Undergoing Prostate Cancer Radiation Therapy

et al. 2016

Self Cite

View full text Add to dashboard Cite

show abstract

“…In patients with peritoneal carcinomas, serum levels of IL-6 and CRP are associated with greater fatigue and somatic symptoms of depression, but not affective symptoms (Low et al, 2014). In prostate cancer patients with non-metastatic disease elevated TNF-α levels in serum are associated with fatigue, depression and anxiety (HADS) (Dirksen et al, 2013). In malignant melanoma patients, sIL6-r levels in serum are negatively associated with self-reported combined affective and somatic symptoms (Self-Reported Depression Scale; SDS) and sTNF-r levels positively associated (Friebe et al, 2007) In metastatic colorectal cancer patients serum IL-6 levels are positively associated with loss of appetite and nausea/vomiting, TGF-β levels are positively associated with loss of appetite and fatigue (Rich et al, 2005).…”

Section: Cancer Patients Prior To Treatmentmentioning

confidence: 99%

Pre-treatment effects of peripheral tumors on brain and behavior: Neuroinflammatory mechanisms in humans and rodents

Schrepf¹,

Lutgendorf²,

Pyter³

2015

Brain, Behavior, and Immunity

View full text Add to dashboard Cite

Cancer patients suffer high levels of affective and cognitive disturbances, which have been attributed to diagnosis-related distress, impairment of quality of life, and side effects of primary treatment. An inflammatory microenvironment is also a feature of the vast majority of solid tumors. However, the ability of tumor-associated biological processes to affect the central nervous system (CNS) has only recently been explored in the context of symptoms of depression and cognitive disturbances. In this review, we summarize the burgeoning evidence from rodent cancer models that solid tumors alter neurobiological pathways and subsequent behavioral processes with relevance to affective and cognitive disturbances reported in human cancer populations. We consider, in parallel, the evidence from human clinical cancer research demonstrating that affective and cognitive disturbances are common in some malignancies prior to diagnosis and treatment. We further consider the underlying neurobiological pathways, including altered neuroinflammation, tryptophan metabolism, prostaglandin synthesis and associated neuroanatomical changes, that are most strongly implicated in the rodent literature and supported by analogous evidence from human cancer populations. We focus on the implications of these findings for behavioral researchers and clinicians, with particular emphasis on methodological issues and areas of future research.

show abstract

“…To date, results are inconclusive, with some studies finding positive associations between fatigue severity and circulating levels of TNF-α [20, 21] and IL-6 [18, 20, 22–29] and others finding no associations with TNF-α[18, 22, 30–33], IL-6 [30, 34–38], and IL-4 [25, 36, 38]. These inconsistent results may be related to the challenges associated with the measurement of serum cytokines, as well as circadian variations in cytokine levels [39].…”

Section: Introductionmentioning

confidence: 99%

Inflammatory pathway genes associated with inter-individual variability in the trajectories of morning and evening fatigue in patients receiving chemotherapy

et al. 2017

View full text Add to dashboard Cite

Fatigue, a highly prevalent and distressing symptom during chemotherapy (CTX), demonstrates diurnal and interindividual variability in severity. Little is known about the associations between variations in genes involved in inflammatory processes and morning and evening fatigue severity during CTX. The purposes of this study, in a sample of oncology patients (N=543) with breast, gastrointestinal (GI), gynecological (GYN), or lung cancer who received two cycles of CTX, were to determine whether variations in genes involved in inflammatory processes were associated with inter-individual variability in initial levels as well as in the trajectories of morning and evening fatigue. Patients completed the Lee Fatigue Scale to determine morning and evening fatigue severity a total of six times over two cycles of CTX. Using a whole exome array, 309 single nucleotide polymorphisms among the 64 candidate genes that passed all quality control filters were evaluated using hierarchical linear modeling (HLM). Based on the results of the HLM analyses, the final SNPs were evaluated for their potential impact on protein function using two bioinformational tools. The following inflammatory pathways were represented: chemokines (3 genes); cytokines (12 genes); inflammasome (11 genes); Janus kinase/signal transducers and activators of transcription (JAK/STAT, 10 genes); mitogen-activated protein kinase/jun amino-terminal kinases (MAPK/JNK, 3 genes); nuclear factor-kappa beta (NFkB, 18 genes); and NFkB and MAP/JNK (7 genes). After controlling for self-reported and genomic estimates of race and ethnicity, polymorphisms in six genes from the cytokine (2 genes); inflammasome (2 genes); and NFkB (2 genes) pathways were associated with both morning and evening fatigue. Polymorphisms in six genes from the inflammasome (1 gene); JAK/STAT (1 gene); and NFkB (4 genes) pathways were associated with only morning fatigue. Polymorphisms in three genes from the inflammasome (2 genes) and the NFkB (1 gene) pathways were associated with only evening fatigue. Taken together, these findings add to the growing body of evidence that suggests that morning and evening fatigue are distinct symptoms.

show abstract

Association of Symptoms and Cytokines in Prostate Cancer Patients Receiving Radiation Treatment

Cited by 21 publications

References 44 publications

Transitions in Symptom Cluster Subgroups Among Men Undergoing Prostate Cancer Radiation Therapy

Transitions in Symptom Cluster Subgroups Among Men Undergoing Prostate Cancer Radiation Therapy

Pre-treatment effects of peripheral tumors on brain and behavior: Neuroinflammatory mechanisms in humans and rodents

Inflammatory pathway genes associated with inter-individual variability in the trajectories of morning and evening fatigue in patients receiving chemotherapy

Contact Info

Product

Resources

About